Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Bausch Health Companies Inc (N:BHC)

Business Focus: Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEC Form 4 filings for BHC*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 16, 2020 06:00 ET
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19
LAVAL, Quebec, Jan. 16, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2019 financial results on Wednesday, Feb. 19, 2020. Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call. ...
Read full article
Jan 13, 2020 06:00 ET
Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference
LAVAL, Quebec, Jan. 13, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") has published a brief company update presentation designed to complement remarks that will be provided by management during a fireside chat at 1:30 p.m. PT (4:30 p.m. ET) today during the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation provides an overview of the Company's recent performance and achievements, including updates on the Company's 2019 commitments and development programs, and offers insight into future goals and catalysts for 2020 and beyond....
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.00
--
--
Price to Sales - TTM
1.18
4.39
5.51
Price to Book - most recent quarter
4.03
2.93
2.95
Price to Cash Flow per share - TTM
6.59
12.11
14.76
Price to Free Cash Flow per share - TTM
7.55
24.19
30.03
See all valuations

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

See business summary

Twitter

Search (past week) for $BHC